

## Fulcrum Therapeutics to Participate in Upcoming December Conferences

November 26, 2024 at 4:05 PM EST

CAMBRIDGE, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.<sup>®</sup> (the "Company") (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in the following conferences:

- Piper Sandler 36<sup>th</sup> Annual Healthcare Conference  
December 3, 2024  
Fireside Chat at 12:00 pm ET, Participation link: [HERE](#)  
New York, New York
- Citi 2024 Global Healthcare Conference  
December 4, 2024  
Miami, Florida
- Evercore ISI 7th Annual HealthCONx Conference  
December 5, 2024  
Miami, Florida

The webcast of the Piper Sandler fireside chat will be accessible by visiting the "Events and Presentations" section of Fulcrum Therapeutics' website at <https://ir.fulcrumtx.com/events-and-presentations>. A replay of the webcasts will be available on Fulcrum Therapeutics' website for at least 30 days following the presentations.

### About Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's lead program in clinical development is pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit [www.fulcrumtx.com](http://www.fulcrumtx.com) and follow us on Twitter/X (@FulcrumTx) and LinkedIn.

### Contact:

Chris Calabrese  
LifeSci Advisors, LLC  
[ccalabrese@lifesciadvisors.com](mailto:ccalabrese@lifesciadvisors.com)  
917-680-5608